Amwise Diagnostic PTE. LTD.

About Amwise Diagnostic We are a leader in precision medicine technology for cancer. Our patented genetic analysis technologies assist doctors and patients in determining the most appropriate individualized treatment strategy that has optimal treatment effectiveness and minimal treatment-related adverse events. Unlike current diagnostic techniques, our innovative technology identifies patients who have a definite high risk of recurrence or metastasis, allowing timely administration of necessary treatment. Our existing product assesses an individual breast cancer patient's need for adjuvant treatment with radiation therapy or chemotherapy. In addition, we have expanded our research into the field of colorectal cancer with the hope of helping more cancer patients in the future. Through strategic partnerships and investment links, we have formulated our plans for the Asian region and have started to plan our entrance into Europe and the United States. We envision our technology benefiting a greater number of patients, leading precision medicine in cancer to the next milestone. About RecurIndex® RecurIndex®, which has undergone large-scale clinical validation, integrates genetic mapping of the genes most related to breast cancer recurrence in Asian patients with clinical factors to predict the 5-year risk of local recurrence and distant metastasis. The test results can help doctors and patients have an earlier understanding of cancer characteristics and can serve as an important reference in the determination of appropriate treatment.